AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Shares Sold by Ironwood Investment Management LLC
Ironwood Investment Management LLC lowered its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 3.0% during the second quarter, Holdings Channel reports. The institutional investor owned 38,354 shares of the specialty pharmaceutical company’s stock after selling 1,192 shares during the period. Ironwood Investment Management LLC’s holdings in AMAG Pharmaceuticals were worth $706,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of AMAG. BlackRock Inc. increased its position in AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after buying an additional 4,988,054 shares in the last quarter. Vanguard Group Inc. increased its position in AMAG Pharmaceuticals by 6.1% in the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after buying an additional 176,832 shares in the last quarter. State Street Corp increased its position in AMAG Pharmaceuticals by 75.2% in the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock worth $56,876,000 after buying an additional 1,082,366 shares in the last quarter. LSV Asset Management increased its position in AMAG Pharmaceuticals by 34.0% in the first quarter. LSV Asset Management now owns 1,685,098 shares of the specialty pharmaceutical company’s stock worth $37,998,000 after buying an additional 427,238 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in AMAG Pharmaceuticals by 777.8% in the first quarter. Acadian Asset Management LLC now owns 1,226,690 shares of the specialty pharmaceutical company’s stock worth $27,659,000 after buying an additional 1,086,937 shares in the last quarter.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 20.10 on Friday. AMAG Pharmaceuticals, Inc. has a 52-week low of $16.00 and a 52-week high of $36.83. The company’s 50-day moving average is $18.77 and its 200-day moving average is $21.08. The firm’s market cap is $704.40 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. The business had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm’s revenue was up 24.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.45 EPS. Equities research analysts forecast that AMAG Pharmaceuticals, Inc. will post $5.40 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/05/amag-pharmaceuticals-inc-nasdaqamag-shares-sold-by-ironwood-investment-management-llc.html.
AMAG has been the subject of a number of research analyst reports. ValuEngine downgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Tuesday, July 11th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $23.00 price objective on shares of AMAG Pharmaceuticals in a research note on Tuesday, May 2nd. BidaskClub raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $34.00 price objective (down previously from $40.00) on shares of AMAG Pharmaceuticals in a research note on Wednesday, May 3rd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $28.09.
In other news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the sale, the senior vice president now directly owns 28,336 shares in the company, valued at approximately $566,720. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 3.80% of the stock is owned by insiders.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.